Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Boston Scientific Corporation is a global medical technology company that designs, manufactures, and markets medical devices used in a wide range of minimally invasive interventional medical specialties. The company operates primarily within the medical devices and healthcare technology industries, focusing on improving patient outcomes while reducing procedural complexity and healthcare costs. Its products are used by physicians and healthcare providers to diagnose and treat complex conditions across cardiovascular, rhythm management, endoscopy, urology, neuromodulation, and oncology care pathways.
The company’s core revenue is driven by its Cardiovascular, Rhythm and Neuro, and MedSurg business segments, which together cover implantable devices, catheters, stents, endoscopic tools, and neuromodulation systems. Boston Scientific serves hospitals, outpatient centers, and specialized clinics globally, with a strategic advantage in its broad product portfolio, strong clinical evidence base, and consistent investment in research and development. Founded in 1979 and publicly listed in 1992, Boston Scientific evolved through organic innovation and targeted acquisitions into one of the world’s largest pure-play medical device companies.
Business Operations
Boston Scientific operates through three primary business segments: Cardiovascular, Rhythm and Neuro, and MedSurg. The Cardiovascular segment includes interventional cardiology and peripheral interventions, offering products such as drug-eluting stents, balloons, and structural heart devices. The Rhythm and Neuro segment encompasses cardiac rhythm management devices, electrophysiology solutions, and neuromodulation systems for chronic pain and neurological disorders. The MedSurg segment includes endoscopy, urology, and pelvic health technologies, serving gastrointestinal, pulmonary, and urologic procedures.
The company generates revenue through direct sales to healthcare providers and distributors, with a significant portion derived from recurring procedural usage. Boston Scientific maintains manufacturing and R&D facilities across multiple countries and holds extensive intellectual property related to minimally invasive technologies. Its operations are supported by a global sales force and long-term relationships with hospitals, clinicians, and group purchasing organizations.
Strategic Position & Investments
Boston Scientific’s strategic direction emphasizes sustainable mid-to-high single-digit organic growth, margin expansion, and leadership in high-growth, minimally invasive therapies. The company consistently invests in internal R&D while complementing innovation through acquisitions that expand its technology base or accelerate entry into adjacent clinical markets. Notable acquisitions include BTG plc, strengthening interventional oncology capabilities, and Lumenis Surgical, expanding its urology portfolio.
The company also holds minority investments and partnerships in emerging medical technology firms, particularly in digital health, robotic-assisted intervention, and next-generation ablation and mapping technologies. Its strategy prioritizes therapies with strong clinical differentiation, durable reimbursement profiles, and long-term procedural growth trends, particularly in cardiovascular disease, chronic pain management, and outpatient procedural settings.
Geographic Footprint
Boston Scientific is headquartered in North America, with its corporate headquarters in Marlborough, Massachusetts, and operates in more than 100 countries worldwide. The company has a substantial presence across Europe, Asia-Pacific, Latin America, and Middle East & Africa, supported by regional headquarters, manufacturing plants, and research centers.
International markets account for a significant and growing portion of total revenue, with emerging markets representing a key long-term growth driver. Boston Scientific’s global footprint enables it to adapt products to local regulatory environments and clinical practices while maintaining centralized innovation and quality systems.
Leadership & Governance
Boston Scientific is led by an experienced executive team with a strategic focus on innovation, operational discipline, and patient-centered care. The company emphasizes a leadership philosophy centered on long-term value creation, ethical governance, and continuous investment in clinical science and talent development.
Key executives include:
- Michael F. Mahoney – Chairman of the Board and Chief Executive Officer
- Daniel J. Brennan – Executive Vice President and Chief Financial Officer
- Joseph M. Fitzgerald – Executive Vice President, Global Operations
- Bradley T. Sorenson – Executive Vice President, Rhythm and Neuro
- Arthur C. Butcher – Executive Vice President, MedSurg
The Board of Directors provides oversight with a focus on corporate governance, risk management, and alignment with shareholder and patient interests.